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Abstract
Background: Mayonnaise is used widely in contemporary human diet with widespread use as a salad dressing or
spread on breads. Vegetable oils used in its formulation may be a rich source of ω-6 PUFAs and the higher-PUFA
content of mayonnaise may be beneficial in mediating a hypocholesterolemic effect. This study, therefore,
evaluated the functionality of mayonnaise on cardiometabolic risk within a regular human consumption scenario.
Methods: Subjects underwent a randomized double-blind crossover trial, consuming diets supplemented with
20 g/day of either soybean oil-based mayonnaise (SB-mayo) or palm olein-based mayonnaise (PO-mayo) for
4 weeks each with a 2-week wash-out period. The magnitude of changes for metabolic outcomes between dietary
treatments was compared with PO-mayo serving as the control. The data was analyzed by ANCOVA using the GLM
model. Analysis was adjusted for weight changes.
Results: Treatments resulted in significant reductions in TC (diff = −0.25 mmol/L; P = 0.001), LDL-C (diff = −0.
17 mmol/L; P = 0.016) and HDL-C (diff = −0.12 mmol/L; P < 0.001) in SB-mayo compared to PO-mayo without
affecting LDL-C:HDL-C ratio (P > 0.05). Lipoprotein particle change was significant with large LDL particles increasing
after PO-mayo (diff = +63.2 nmol/L; P = 0.007) compared to SB-mayo but small LDL particles remained unaffected.
Plasma glucose, apolipoproteins and oxidative stress markers remained unchanged.
Conclusions: Daily use with 20 g of linoleic acid-rich SB-mayo elicited reductions in TC and LDL-C concentrations
without significantly changing LDL-C:HDL-C ratio or small LDL particle distributions compared to the PO-mayo diet.
Trial registration: This clinical trial was retrospectively registered with the National Medical Research Register,
National Institute of Health, Ministry of Health Malaysia, (NMRR-15-40-24035; registered on 29/01/2015; https://www.
nmrr.gov.my/fwbPage.jsp?fwbPageId=ResearchISRForm&fwbAction=Update&fwbStep=10&pk.
researchID=24035&fwbVMenu=3&fwbResearchAction=Update). Ethical approval was obtained from the National
University of Malaysia’s Medical Ethics Committee (UKM 1.5.3.5/244/SPP/NN-054-2011, approved on 25/05/2011).
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Background
Therapeutic lifestyle changes that address dietary cor-
rection are core principles to prevent chronic disease
burden. The United States Dietary Guidelines (USDG)
Technical Report in 2015 [1] dropped dietary choles-
terol from the list of ‘nutrients of concern’ in relation
to the chronic disease burden. This update is in con-
cordance with the lack of evidence from clinical studies
showing a benefit in dietary cholesterol reduction [2].
Instead, the USDG Technical Report has emphasized
substituting saturated fats with polyunsaturated fatty
acid (PUFA) alternatives as part of healthy dietary rec-
ommendations [1]. Based on controlled feeding trials,
the strength of evidence is rated as strong for every 1 %
of energy from saturated fatty acid (SFA) that is re-
placed with PUFA which produces a 1.8 mg/dL de-
crease in low density lipoprotein-cholesterol (LDL-C)
[3]. The consumption of PUFA-enriched foods, mainly
from the ω-6 family, is therefore necessary in order to
make this recommendation actionable. The relationship
between SFA and PUFA intakes in general populations,
shows that lower intakes of SFA are not accompanied
by higher intakes of PUFA, as is recommended for pre-
venting coronary heart disease [4]. In this regard, the
nutraceutical actions of functional food ingredients are
been explored as either adjuvant or alternate therapy to
pharmacological interventions [5].
PUFA availability in the human diet is further differen-
tiated into ω-3 and ω-6 fatty acid classes. The ω-3
PUFAs are involved in prostaglandin E3, prostaglandin
I3 and thromboxane A3 production while ω-6 PUFAs
are involved in the production of prostaglandin E2, pros-
taglandin I2 and thromboxane A2; and these two fatty
acid classes are known to exhibit antagonistic effects.
Looking at effects on serum lipids, it has been reported
that ω-3 PUFAs lower triglycerides thereby benefiting
dyslipidemia management whereas ω-6 PUFAs, specific-
ally linoleic acid, cause decreased LDL-C concentrations
[5]. Global data on country-specific ω-6 consumption
ranges between 1.2 and 12.5 % of energy, with a global
mean of 5.9 % energy [6]. Therefore, in practice, there is
dietary insufficiency of ω-6 PUFA in the human diet in
most countries, and the recommendation to increase
PUFA for cardiovascular disease (CVD) prevention re-
quires some degree of dietary supplementation. In con-
trast, although ω-3 PUFAs have a secondary prevention
role in CVD mortality, it is ω-6 PUFA that is perceived
to have an etiological effect as a replacement for SFA in
reducing LDL-C [6]. A long-term prospective cohort
running for 32 years showed ω-6 PUFA intake, especially
linoleic acid, was inversely associated with mortality
from major CVD causes [7].
Mayonnaise is a mainstay in the contemporary human
diet with widespread use as a salad dressing in the home
or restaurant. Traditional mayonnaise is a source of ω-6
PUFAs depending on the source of compositional oils
which may be from soybean, canola, corn or sunflower
sources [8]. The functional role of fat in mayonnaise for-
mulation is in maintaining food quality related to tex-
ture, flavor, and stability of food emulsion products [9].
The PUFA content of mayonnaise ranges between 28.0
and 47.9 g/100 g product [10]. Most regular mayonnaise
products produced commercially are formulated with
soybean oil (SB). SB contains a significant proportion of
linoleic acid (LA, 18:2 > 50 %) and less palmitic acid
(16:0 < 10 %) and being PUFA-rich would be expected to
contribute to a hypocholesterolemic effect [11]. However
if this is true, no literature has reported on the cholester-
olemic lowering effect of mayonnaise if consumed con-
sistently over a period of time. On the other hand,
Amini et al. [12], who conducted a cross-sectional exam-
ination of adult Iranian diets (n = 425), suggested may-
onnaise as part of an undesirable Western-pattern diet
matrix was associated with risk of metabolic syndrome
(MetS). This view differs from a Japanese study which in
examining associations between major dietary patterns
and MetS prevalence, reported mayonnaise was not
associated with prevalence of MetS, but was positively
associated with high blood glucose [13].
Although, coronary risk is assessed in terms of athero-
sclerosis development [3], the wider scope today in-
cludes MetS, with inflammation and oxidative stress
implicated in its early pathology [14–16]. Our key re-
search question therefore was- given the fatty acid com-
positional profile of mayonnaise if consumed on a daily
basis- what would be its direct impact on lipid and lipo-
protein profile? On a wider scope, what would be the
impact on other metabolic parameters related to oxida-
tive stress and inflammation? An additional interest in
this study was to also address an issue whether subclass
differences in LDL and high density lipoprotein (HDL)
particle profiles were responsive to the manipulated lino-
leic acid content of the total diet.
Methods
Subject demographics
The study was conducted at a teachers’ training institute
and subjects were recruited via the institutional notice-
board. Initially 36 healthy Malaysian subjects without a
history of atherosclerotic disease, diabetes or hyperten-
sion were recruited but 2 subjects withdrew voluntarily
in the first week of the trial as they were unwilling to
conform to the study protocol. Finally, 16 men and 18
women participated with mean prescreening plasma
total cholesterol (TC) levels of 5.01 ± 0.54 mmol/L but
classified into 2 groups – either normocholesterolemic
values (n = 21, <5.2 mmol/L) or with mild/borderline
hypercholesterolemia (n = 13, 5.2-6.0 mmol/L). Overall
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mean (±SD) characteristics for subjects who qualified,
signed informed consent and completed the study were:
age = 23.36 ± 6.98 year, body weight = 64.49 ± 14.41 kg
and body mass index (BMI) = 25.08 ± 4.71 with plasma
values for TC = 5.01 ± 0.54 mmol/L, HDL-C =1.39 ±
0.30 mmol/L, LDL-C = 3.18 ± 0.48 mmol/L, triacylglyc-
erol (TAG) = 0.99 ± 0.46 mmol/L and fasting glucose =
4.70 ± 0.44 mmol/L (Table 1).
Study design
A 2-period cross-over design with a 2-week wash-out
between rotations of 4 weeks each was adopted for the
study. Subjects were randomized between 2 groups of 17
each with both groups on parity for gender, age and
plasma TC levels. For each 4-week rotation, one group
received as test a soybean-based mayonnaise product
(SB-mayo) with the background diet whilst the other
group received a palm olein-based mayonnaise product
(PO-mayo) serving as a control with the similar back-
ground diet. The purpose of using a PO-based mayo in
the control diet was to optimize it as a habitual diet re-
flective of a higher SFA content. The cross-over of diet
treatments took place after completion of the 2-week
wash-out period following the first 4-week feeding
period. In the 2-week wash-out period subjects were
allowed to return to free living conditions and consume
their habitual diets ad libitum. Researchers and subjects
were blinded to test mayonnaise products which were
labeled as Mayo A or Mayo B. Only the study dietitian
serving as the controller knew the mayonnaise codes
and was responsible for assigning the sandwiches made
with test mayonnaise to the respective groups. Figure 1
indicates the flow chart for this study.
This study was conducted in accordance with the prin-
ciples of the Declaration of Helsinki with ethical ap-
proval provided by the National University of Malaysia’s
Medical Ethics Committee (UKM 1.5.3.5/244/SPP/NN-
054-2011 approved on 25/05/2011).
Test mayonnaise products
The amount of mayonnaise planned for daily consump-
tion during this trial was based on a test fat load re-
quired to elicit lipid and lipoprotein changes in an
overall daily diet deriving ~30 %-en from total dietary
fats as reported in our previous studies [17–19]. The
calculated fat was provided by an equivalent of ~20 g
mayonnaise per subject for each trial feeding day and
when incorporated into sandwiches resulted in an esti-
mated 15 g of respective test fat load delivery. These
sandwiches were made by the study dietitian serving as
the controller, who was responsible for assigning the
sandwiches as per test mayonnaise code to the subjects.
The completely formulated test product (SB-mayo) was
supplied in pre-packed sachets whereas the control
(PO-mayo) was provided only as egg slurry similar in
composition to the SB-mayo (R&D Division Kewpie
Corporation, Japan, and Kewpie Malaysia Sdn. Bhd,
Malaysia). The control egg slurry was emulsified daily
by the study dietitian with an amount of palm olein
equivalent to the soybean oil content in the SB-mayo.
This daily emulsification process was necessary as
otherwise this mayonnaise product could not hold sta-
bility. Table 2 indicates the percent fatty acid compos-
ition (FAC) of the 2 mayonnaise products used in the
study. Only statistically significant differences (P < 0.05)
between the 2 products were related to palmitic, oleic,
linoleic and linolenic acid content.
Test diets
As study subjects were residing on campus in the
study site, all meals inclusive of breakfast, lunch, tea
and dinner for each fat rotation were provided by the
institutional caterer as instructed by the research
dietitian. Subjects were expected to consume these
meals at a designated residential cafeteria supervised
by the dietitian. A standardized 7-day cycle menu
planned with a fixed daily total fat and cholesterol
content was used for the two 4-week test rotations.
All meals were cooked with palm olein to fix the
background fat for meal preparation and were stan-
dardized to recipes, portion sizes and procedures for
incorporating the cooking oil. The amount of cooking
oil used was enough to maintain a reduced fat back-
ground (~25 %-en) allowing subjects in the 2 test
rotations ~45 g per day of palm olein whilst ~15 g of
fat was derived from the test mayonnaise during the
feeding trial. Other sources of SFAs such as lauric
and myristic acids were limited in the menu by
excluding coconut-based products and full-fat dairy
products. Skim milk and a limit of 2 eggs per week
Table 1 Subject characteristics
Characteristics Overall (n = 34)
Gender (M/F) 16/18
Age (yr) 23.4 ± 7.0
Body weight (kg) 64.5 ± 14.4
BMI (kg/m2) 25.1 ± 4.7
TC (mmol/L) 5.01 ± 0.54
HDL-C(mmol/L) 1.39 ± 0.30
LDL-C(mmol/L) 3.18 ± 0.48
TAG (mmol/L) 0.99 ± 0.46
Glucose (mmol/L) 4.70 ± 0.44
All blood parameters are based on plasma analysis; Values represent mean ±
SD of 34 subjects
Abbreviations: BMI body mass index, TC total cholesterol, HDL-C high density
lipoprotein-cholesterol, LDL-C low density lipoprotein-cholesterol,
TAG triacylglycerol
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Fig. 1 The flow chart for the study design
Table 2 Percent fatty acid composition (%) of mayonnaise products, duplicated diets and plasma triacylglycerol
Fatty acids (%) Mayonnaise products Duplicated total diets b Plasma triacylglycerol




C12:0 0.03 0.29 0.37 ± 0.29 0.51 ± 0.41 0.43 ± 0.06 0.49 ± 0.35 0.36 ± 0.64
C14:0 0.07 0.90 0.79 ± 0.12 0.95 ± 0.35 1.57 ± 0.70 1.14 ± 0.47 0.99 ± 0.41
C16:0 10.4 37.7 28.0 ± 2.9* 34.6 ± 1.7* 32.1 ± 2.3 29.6 ± 1.7* 31.2 ± 1.7*
C16:1ω7 0.15 0.16 0.55 ± 0.12 0.62 ± 0.17 4.09 ± 0.81 4.26 ± 0.87 4.21 ± 1.11
C18:0 3.51 2.78 4.40 ± 0.93 4.23 ± 0.52 4.09 ± 1.17 3.16 ± 0.64 3.08 ± 0.52
C18:1 24.3 45.1 37.5 ± 1.2* 41.8 ± 1.7* 40.9 ± 2.3 40.9 ± 2.3* 43.7 ± 1.7*
C18:2ω6 53.1 12.3 23.4 ± 3.5* 13.0 ± 1.7* 12.0 ± 1.7 15.3 ± 1.2* 12.7 ± 1.7*
C18:3ω6 nd nd 0.18 ± 0.12* 0.04 ± 0.35* 0.24 ± 0.12 0.20 ± 0.12 0.15 ± 0.06
C18:3ω3 5.56 0.29 1.05 ± 0.41 0.77 ± 0.87 0.30 ± 0.12 0.35 ± 0.12 0.26 ± 0.17
C20:4ω6 nd nd 0.10 ± 0.58 0.15 ± 0.93 0.57 ± 1.98 0.62 ± 0.23 0.59 ± 0.23
Total SFA 14.0 41.7 35.1 ± 2.8* 41.9 ± 1.3* 37.9 ± 3.3 34.3 ± 2.4* 35.5 ± 2.2*
Total MUFA 24.5 45.3 38.5 ± 1.3* 42.8 ± 1.8* 45.0 ± 2.5 45.1 ± 2.6* 47.9 ± 2.0*
Total PUFA 58.7 12.6 25.7 ± 3.6* 14.4 ± 0.9* 12.9 ± 2.3 16.3 ± 1.4* 13.4 ± 1.9*
Total ω-6 53.1 12.3 24.0 ± 3.7* 13.2 ± 1.0* 12.7 ± 2.2 15.5 ± 3.1* 13.1 ± 1.8*
Total ω-3 5.56 0.29 1.05 ± 0.41 0.77 ± 0.87 0.28 ± 0.14 0.35 ± 0.13 0.26 ± 0.15
ω-6:ω-3 ratio 9.55 42.4 26.7 ± 11.9 24.2 ± 9.6 48.0 ± 14.2 55.7 ± 31.5 71.4 ± 71.4
id 97.12 99.52 96.34 96.67 96.29 96.02 97.24
a unid 2.88 0.48 3.66 3.33 3.71 3.98 2.76
Abbreviations: C carbon chain length, MUFA mono-unsaturated fatty acids, SB-mayo soybean oil-based mayo, PO-mayo palm olein-based mayo, PUFA poly-
unsaturated fatty acids, nd not detected, id identified, SFA saturated fatty acids, unid unidentified, ω-6 omega 6, ω-3 omega 3
apercent unidentified fatty acids constitute <4 % of total fatty acid composition
bRepresents total daily diet planned as per a research menu and FAC analyses is performed from duplicate diets collected from subjects. Values
represent mean ± SD
*significance shown with P < 0.05
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were allowed. The daily diets provided a total of 62–
64 g of fat; the SB-mayo diet carrying 12 g of linoleic
acid (~1/3rd of total fat) from the mayonnaise yielded
final concentrations of 23.4 % 18:2ω6 and 1.05 %
18:3ω3 vs 13.0 % 18:2ω6 and 0.77 % 18:3ω3 in the
PO-mayo based diet. Thus for the total diet compari-
sons, the total ω6 was significantly higher in SB-mayo
compared to PO-mayo treatment. Subjects were
instructed to eat according to their usual capacity for
food intake as determined by energy intake assess-
ment from 24-h diet records at baseline. This pre-
study energy intake assessment provided a guideline
to the dietitian for ensuring monitoring subjects’
weight fluctuations did not exceed 1 kg within each
4-week test rotation.
Compliance measures
For each rotation these included [i] meal time attend-
ance records [ii] weekly recording of body weights of
subjects [iii] collecting 3 × 24-h diet records per rotation
from every subject and [iv] preparing duplicated diets of
all foods consumed over a 24-h period including snacks
and fluids except water from subjects for FAC analysis.
The 24-h diet records were analyzed with NutriPro
software [version 3.2.0] which includes databases for
Malaysian foods [20].
Blood collection and analyses
All subjects arrived at the laboratory after an overnight
fasted state (~10 h) on testing days at baseline, day 27
and day 28 of each test rotation. Blood was collected
into Vacutainer® tubes (Becton Dickinson Vacutainer, NJ,
USA) containing EDTA (0.117 ml of 15 % EDTA) and
immediately centrifuged at 3000 g for 10 min at 4 °C
(Sigma 3 K12 B.Braun, Germany) to separate plasma
from red blood cells. Plasma aliquots were snap-frozen
in liquid nitrogen and stored at −80 °C for analyses after
study completion. To reduce intra-variations in the ana-
lysis, plasma samples were analyzed in a single batch.
Analyses of lipids and lipoproteins
Analyses were carried out using automated clinical
chemistry procedures. Enzymatic kits were used to
measure plasma TC, TAG and HDL-C (Roche Diagnos-
tics Corporation, Indianapolis, IN, USA). For the deter-
mination of cholesterol and TAG concentrations the
assay procedures were based on Allain et al. (1974) and
Nägele et al. (1984), respectively [21, 22]. The Cobas
Integra HDL-Cl plus 2nd generation in vitro diagnostic
kit, for the direct determination of HDL-C, combines
polyethylene glycol-modified enzymes with sulphated α-
cyclodextrins [23]. These assays were performed using a
Cobas 6000 Chemistry Autoanalyzer System (Roche
Analytic Instruments Inc, Nutley, NJ, USA). Reagents,
calibrators and controls were also supplied by the manu-
facturer (Roche Diagnostics Corporation, Indianapolis,
IN, USA). LDL-C was calculated using the Friedewald
equation [24]. Very low density lipoprotein-cholesterol
(VLDL-C) was calculated by multiplying TAG values by
a factor of 0.46.
Determination of glucose
Plasma glucose was assessed by the hexokinase –glucose-
6-phosphate dehydrogenase 2-step enzymatic procedure
[25]. An in vitro diagnostic reagent kit for this enzymatic
procedure, Glucose HK Liquid (GLUCL 0–992) (Roche
Diagnostics Corporation, Indianapolis, IN, USA) was used
for automated analysis (Roche Analytic Instruments Inc,
Nutley, NJ, USA).
Determination of non-esterified fatty acids (NEFA)
Plasma NEFA was assessed by the acyl-CoA synthase-
acyl CoA oxidase-peroxidase (ACS-ACOD) 3-step
enzymatic procedure [26] using a commercial kit, Lab
Assay™ NEFA (Wako pure chemical industries Ltd.,
Osaka, Japan) with absorbance detected at 550 nm by a
multi-detection microplate reader (Powerscan® HT, DS
Pharma Biomedical Co. Ltd., Osaka, Japan).
Determination of apolipoproteins (apo) A1 and B
Plasma apolipoproteins were assessed by the sandwich
ELISA procedure using anti-human apoA1 or apoB
monoclonal antibody, and horseradish peroxidase-
labeled anti-human apoA1 or apoB monoclonal anti-
body, respectively [27]. A commercial kit, ELISApro kit
for Human ApoA1, or ApoB [Mabtech Inc., OH, USA]
was used with absorbance detected at 450 nm by a
multi-detection microplate reader [Powerscan® HT, DS
Pharma Biomedical Co. Ltd., Osaka, Japan].
Determination of thiobarbituric acid reactive substances
(T-BARs)
T-BARs was assessed by the malondialdehyde-TBA
adduct formed by the reaction of malondialdehyde
and T-BARs [28] under high temperature (90–100 °C)
using a commercial kit, T-BARs assay kit (Cayman
Chemical Company, MI, USA). Acidic conditions
were detected by measuring absorbance at 550 nm
with a multi-detection Microplate reader (Powerscan®
HT, DS Pharma Biomedical Co. Ltd., Osaka, Japan).
Determination of high sensitivity C-reactive protein (hsCRP)
Plasma hsCRP was assessed by a sandwich ELISA protocol
with a commercial kit (Helica Biosystems Inc., CA, USA)
which uses anti-human CRP monoclonal antibody, and
horseradish peroxidase-labeled anti-human CRP mono-
clonal antibody [29]. Absorbance at 450 nm was detected
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by a multi-detection microplate reader (Powerscan® HT,
DS Pharma Biomedical Co. Ltd., Osaka, Japan).
NMR lipoprotein particle measures
Particle count and particle size profile determinations
for LDL and HDL were carried out by automated
nuclear magnetic resonance (NMR) spectroscopic assay
by an independent laboratory (LipoScience Inc., Raleigh,
North Carolina, USA). EDTA plasma samples held at
−80 °C at study conclusion were shipped out in dry ice
to the certified laboratory (CLIA ID No. 34D0952253) as
per service provider instructions. The NMR technology
streamlines the time-consuming ultracentrifugation
process into a 2-step analytical process using automated
NMR signal acquisition followed by computational
analysis [30].
Analyses of fatty acid composition
Test mayonnaise, duplicated diets and total plasma were
subjected to FAC analysis using methodology as de-
scribed previously [17–19]. FAC analysis was carried out
by means of gas chromatography (Shimadzu Scientific
Instruments, Japan). The fatty acid profile of analyzed
meals served to check whether research diets achieved
fatty acid targets. FAC determination of plasma TAG
served to check subjects’ compliance to targeted mayon-
naise consumption in each test fat rotation as per
research protocol.
Statistical analysis
A cross-over design was used which enabled subjects to
serve as their own control. For each subject, the mean
value for day 27 and day 28 in each treatment rotation
was taken as the end point. In descriptive statistics, data
were expressed as mean ± SD and the level of significance
was set as P < 0.05. We deduced that the 2-week washout
period between treatments was sufficient by comparing
values for the 2 baselines by paired sample t-test analysis
and found a lack of significance (P > 0.05). Within and
between treatment comparisons of targeted fatty acids in
plasma triglycerides expected to be reflective of mayon-
naise treatment were analyzed by ANCOVA analysis using
GLM model. Weight change between treatment periods
was analyzed for statistical significance on metabolic out-
comes. However, all analysis to test difference in means
for metabolic outcomes were carried out controlled for
weight changes by ANCOVA procedure using GLM
model. The magnitude of changes for metabolic outcomes
between dietary treatments was compared with PO-mayo
serving as the control for comparison and data was
analyzed by ANCOVA using the GLM model. The Statis-
tical Package for Social Sciences, SPSS® for Windows™
application (Version 18.0, SPSS Inc., Chicago, USA) was




Weight reductions occurred for both rotations (SB-mayo
= −0.6 ± 1.1 kg, P = 0.003 and PO-mayo = − 0.9 kg ± 1.1 kg,
P < 0.001) compared to baseline. However, mean weight
loss at the end of the study periods was less than 1 kg and
not significantly different between groups (P > 0.05). This
weight change did not influence metabolic outcomes or
lipoprotein particle size distributions (P > 0.05).
FAC analysis of diets and plasma TAG
Targeted palmitic, oleic, linoleic and linolenic acids of
duplicated diets collected from subjects during each test
rotation were significantly different (P < 0.001) between
SB-mayo and PO-mayo diets (Table 2). Similarly,
consumption of these diets reflected in within- and
between-diet effects specific to palmitic, oleic and lino-
leic acids that were significantly different (P < 0.05) as
indicated by FAC analysis of plasma TAG (Table 2). No
difference in arachidonic acid (%) in plasma TAG was
apparent between dietary treatments (P > 0.05).
Nutrient intake
Subjects’ consumption of calories, protein, carbohydrate,
fat, cholesterol and fiber were similar (P > 0.05) in both
arms of the study but only SFA, monounsaturated fatty
acid (MUFA) and PUFA content were significantly differ-
ent (P < 0.001) between test rotations (Table 3).
Metabolic outcomes
Changes in lipid and lipoprotein parameters as a result of
manipulating the mayonnaise content of the diet occurred
Table 3 Nutrient composition of consumed diets per day
Nutrients Dietary recalls a
SB-mayo PO-mayo
Energy (kcal) 1938 ± 279 1994 ± 356
Protein (g) 57.6 ± 11.7 58.9 ± 14.0
CHO (g) 284 ± 52 293 ± 64
Fat (g) 62.2 ± 8.2 64.1 ± 9.9
Cholesterol (mg) 147 ± 41 151 ± 41
SFA (%) 7.8 ± 1.4* 10.9 ± 1.8*
MUFA (%) 9.4 ± 1.2* 11.6 ± 1.8*
PUFA (%) 12.0 ± 2.2* 6.8 ± 1.8*
Fiber (g) 6.27 ± 1.63 6.58 ± 2.86
Abbreviations SB-mayo soybean oil-based mayo, PO-mayo palm olein-based
mayo, CHO carbohydrate, SFA saturated fatty acids, MUFA monounsaturated
fatty acids, PUFA polyunsaturated fatty acids
*significance shown with P < 0.05
aDiet recall nutrient values (mean ± SD of 34 subjects) were based on 3 × 24-h
diet recalls collected for each subject for each test rotation and calculated
from a reference nutrient database (First Databank, 2005)
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as indicated in Table 4. After adjustment for baseline,
effects attributable to dietary treatment alone were:
i. SB-mayo treatment significantly reduced
TC compared to the PO-mayo diet
(diff = −0.25 ± 0.40 mmol/L; P = 0.001).
ii. LDL-C reduction was significantly greater after the
SB-mayo treatment compared to the PO-mayo
treatment (diff = −0.17 ± 0.40 mmol/L; P = 0.016).
iii. Reduction in HDL-C concentration was associated
with the SB-mayo dietary treatment which was
significantly lower from the PO-mayo treatment
(diff = −0.12 ± 0.15 mmol/L; P < 0.001).
iv. Changes in LDL-C:HDL-C ratio between diets were
not significant (P > 0.05).
v. Plasma TAG, VLDL-C and glucose changes between
dietary treatments were not significant (P > 0.05).
vi. A non-significant decreasing effect of SB-mayo
treatment on apoB concentrations (diff = −5.86 ±
18.26 mg/mL; P = 0.07) was noted compared to
PO-mayo treatment, whereas apoA1 levels were
not affected (P > 0.05).
Lipoprotein particle measures
Table 5 provides distribution data for lipoprotein particle
patterns analyzed for LDL and HDL particles for 31
subjects (3 subjects were excluded because plasma
volume was insufficient). Dietary treatment did not
significantly affect total HDL particle count (THP) or
size distributions (P > 0.05).
However, dietary treatment effect was associated
with LDL particle size distributions specific to inter-
mediate LDL (IL) and large LDL (LL) without any
change (P > 0.05) in total LDL particle count (TLP).
Overall, significant reductions in LL (diff = −63.2 ±
122.2 nmol/L, P = 0.007) and IL (diff = −9.50 ±
24.61 nmol/L, P = 0.040) particles occurred as a result
of SB-mayo treatment compared to PO-mayo treat-
ment. Treatment effects on small LDL (SL) were not
apparent. Alteration in LDL subclass composition
however did not result in differences in mean LDL
particle size due to treatments.
Markers of oxidative stress
NEFA, T-BARs and hsCRP outcomes were not signifi-
cantly different (P > 0.05) between dietary treatments.
Discussion
The 20 g exchange of test mayonnaise effectively
reflected either linoleic (18:2) or palmitic (16:0) acid
availability with dietary cholesterol equal between both
diets. As intentioned, plasma fatty acid composition
reflected higher percentages of palmitic and oleic acids
(18:1) when subjects consumed PO-mayo or a linoleic
acid (18:2, LA) with the SB-mayo.
Significant reductions in TC and LDL-C concentrations
were associated with the SB-mayo rotation compared to
the control mayonnaise. It was possible that these reduc-
tions were attributed to the higher LA availability from
the SB-mayo as it is well established that LA reduces
plasma cholesterol concentrations [31, 32]. Concomitant
with this approach, it is said that diets lower in SFA and
greater in PUFA content result in better CVD outcomes
[1, 32, 33]. Substitution with PUFA for SFA was shown to
lower CVD risk in the Medical Research Council study
[34], where a high PUFA-rich SB feeding (20.4 %-en) com-
pared to SFA as control (PUFA at 4.4 % - en) resulted in
reduced number of cardiac events (rr = 0.86, 95 % CI 0.61,
Table 4 Metabolic parameters in response to mayonnaise diets












TC (mmol/L) 5.20 ± 0.56 4.80 ± 0.65 5.06 ± 0.61 −0.25 ± 0.40 <0.001 0.010 0.001 (0.63)
LDL-C (mmol/L) 3.37 ± 0.52 3.05 ± 0.57 3.22 ± 0.57 −0.17 ± 0.40 <0.001 0.020 0.016 (0.43)
HDL-C (mmol/L) 1.39 ± 0.27 1.21 ± 0.27 1.34 ± 0.30 −0.12 ± 0.15 <0.001 0.090 <0.001 (0.80)
TAG (mmol/L) 0.94 ± 0.36 1.13 ± 0.54 1.08 ± 0.45 0.05 ± 0.28 <0.001 0.010 0.285 (0.18)
VLDL-C (mmol/L) 0.51 ± 0.19 0.61 ± 0.29 0.58 ± 0.25 0.03 ± 0.15 <0.001 0.010 0.285 (0.20)
LDL-C:HDL-C 2.54 ± 0.72 2.67 ± 0.87 2.56 ± 0.80 0.12 ± 0.41 0.070 0.820 0.106 (0.29)
ApoA1 (mg/mL) 138 ± 20 126 ± 19 124 ± 19 2.00 ± 22.31 <0.001 <0.001 0.605 (0.09)
ApoB (mg/mL) 119 ± 23 111 ± 26 117 ± 25 −5.86 ± 18.26 0.040 0.700 0.070 (0.32)
Glucose (mmol/L) 4.76 ± 0.37 4.92 ± 0.32 4.95 ± 0.30 −0.04 ± 0.30 0.020 0.010 0.475 (0.13)
NEFA (mEq/L) 0.54 ± 0.19 0.49 ± 0.17 0.49 ± 0.15 0.00 ± 0.15 0.080 0.120 0.963 (0.00)
T-BARs (mg/mL) 1.19 ± 0.77 1.22 ± 0.79 1.15 ± 0.66 0.06 ± 0.53 0.840 0.820 0.483 (0.11)
hsCRP (mg/mL) 0.22 ± 0.28 0.16 ± 0.21 0.19 ± 0.21 −0.03 ± 0.28 0.240 0.600 0.492 (0.11)
Values are reported as mean ± SD of 34 subjects; significance is at P <0.05. All values were adjusted for change in body weight
Abbreviations: TC total cholesterol, HDL-C high density lipoprotein-cholesterol, LDL-C low density lipoprotein-cholesterol, TAG triaclyglycerol, VLDL-C very low
density lipoprotein-cholesterol, NEFA non-esterified fatty acids, T-BARs thiobarbituric acid, hsCRP high sensitive C-reactive protein, ES effect size
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1.22). The Finnish Mental Hospital Study reported lower
mortality when SB replaced regular SFA-containing
dairy products in both men (rr = 0.55, 95 % CI 0.34,
0.88) [35] and women (rr = 0.64, 95 % CI 0.41, 1.00)
[36]. These were intervention trials running for 6 years
with PUFA provided at 12.9 % of total calories com-
pared to its content in the control diet at 4.3 % of total
calories in the present study. The St. Thomas’Atheroscler-
osis Regression Study reported a displacement of SFA with
PUFA resulted in reversing atherosclerosis with the great-
est regression in those reporting consumption of the least
amount of SFA [37]. The Atherosclerosis Risk in Commu-
nities Study indicated the highest quartile of circulating
cholesteryl linoleate after the LA-enriched diet was associ-
ated with lower carotid artery intimal medial thickness
[38].
Subjects on the PO-mayo nevertheless experienced a
small reducing effect of TC and LDL-C from baseline
which could be attributed to its higher oleic acid (18:1)
content. Indeed percent oleic acid in plasma after com-
pleting the PO-mayo phase was greater (by ~3 %) com-
pared to baseline or during the SB-mayonnaise rotation.
MUFA coexists with SFA in many foods which would be
true as indicated by the fatty acid composition of palm
olein which contains on average 45 % of oleic acid and
39 % of palmitic acid compared to 22 and 11 % respect-
ively for these fatty acids in SB [9]. Additionally, com-
parison of palm olein and olive oil in human feeding trials
indicate that dietary palmitic and oleic acids exert similar
effects on plasma lipoproteins [39, 40]. Reduction in diet-
ary SFA intake is also associated with a fall in HDL-C
concentrations depending on the substituting nutrient ex-
change [32]. LA’s additional role in lipoprotein metabolism
is in mediating a reducing effect on HDL-C concentrations
[31]. We observed this effect when subjects were consum-
ing the LA-rich SB-mayo but not with the PO-mayo. How-
ever, LDL-C:HDL-C ratios were not affected. We also
noted this HDL-C reduction did not affect total HDL lipo-
protein particle number or size distributions.
The LA-enriched diet that included the SB-mayo
did not result in an expected significant decrease in
apoB concentrations. ApoB is a surrogate measure for
atherosclerotic lipoprotein particles as more than
90 % of apoB is carried by LDL particles [41]. LDL
lipoprotein subclass distribution is directly implicated
in atherogenesis with reduced large buoyant LDL par-
ticles and increased small dense LDL particles favour-
ing atherosclerotic plaque deposition [42, 43]. We
investigated LDL lipoprotein particle distribution and
found an overall 3 % decrease in total LDL particle
translated into significant 19.6 % decrease in inter-
mediate LDL particles and also an 11 % decrease in
large LDL particles, without a significant change in
small LDL particles when subjects were regularly con-
suming the SB-mayo. Previous interventions have re-
ported standard [44] or high dose dietary cholesterol
[45] feeding did not cause shifts in LDL particle size
irrespective of cholesterolemic status. Thus it is prob-
able that the shifts in LDL lipoprotein particle distri-
butions observed in our study could be attributed to
the enriched-LA diet which was exchanged for
palmitic acid.
Table 5 Lipoprotein particle count and lipoprotein particle size distribution as per dietary treatment













TL 1165 ± 318 1094 ± 327 1129 ± 310 −35.0 ± 169.4 0.050 0.190 0.259 (0.21)
LL 574 ± 137 500 ± 151 563 ± 143 −63.2 ± 122.2 0.010 0.540 0.007 (0.52)
IL 48.4 ± 31.7 27.5 ± 33.5 37.0 ± 26.0 −9.50 ± 24.61 <0.001 0.020 0.040 (0.39)
SL 543 ± 363 567 ± 377 530 ± 372 37.7 ± 227.8 0.010 0.540 0.365 (0.17)
Mean LDL particle size (nm)
21.6 ± 0.70 21.4 ± 0.77 21.6 ± 0.71 −0.15 ± 0.48 0.190 0.750 0.095 (0.31)
HDL particles (μmol/L)
TH 31.2 ± 3.71 28.7 ± 3.62 29.4 ± 3.28 −0.67 ± 2.56 <0.001 <0.001 0.154 (0.26)
HL 8.5 ± 2.98 7.8 ± 2.77 7.98 ± 2.66 −0.16 ± 1.45 0.090 0.080 0.558 (0.11)
HM 3.25 ± 2.09 2.46 ± 1.65 2.42 ± 2.42 0.04 ± 2.02 0.090 0.090 0.918 (0.02)
HS 19.5 ± 4.24 18.4 ± 4.06 19.0 ± 3.80 −0.56 ± 3.10 0.120 0.290 0.326 (0.18)
Mean HDL particle size (nm)
9.2 ± 0.46 9.2 ± 0.44 9.2 ± 0.47 −0.05 ± 0.19 0.490 <0.001 0.155 (0.26)
Values are reported as mean ± SD of 31 subjects; significance is at P < 0.05. All values were adjusted for change in body weight
Abbreviations: TL total particle count for LDL, IL intermediate LDL, LL large LDL and SL small LDL particle concentrations, TH total particle count for HDL, HL large
HDL, HM medium HDL and HS small HDL particle concentrations. ES effect size
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A major concern with higher LA consumption is the hy-
pothesis it could promote an inflammatory environment
central to chronic disease development [46]. One pathway
is LA-induced arachidonic acid (20:4ω6) enrichment in
tissue phospholipids would lead to excessive generation of
pro-inflammatory eicosanoids [46, 47]. A systematic re-
view examining Western-type diets did not find, after diet-
ary manipulation, changes in plasma or serum arachidonic
acid levels despite a 6-fold increase in dietary LA con-
sumption or up to 90 % reduction in LA [47]. Our study
too did not find this effect. Another systematic review of
randomized controlled trials, assessing addition of LA to
the diet of healthy non-infant populations, did not find
any evidence that LA increased the concentration of
biologic markers of chronic inflammation including CRP,
fibrinogen, plasminogen activator inhibitor type 1, cyto-
kines, soluble vascular adhesion molecules, or tumour
necrosis factor-α [48]. We included only hsCRP as an in-
flammatory marker in our study but this marker was not
significantly affected after consumption of the LA-rich
diet enriched by the SB-mayo addition.
The capacity of mayonnaise to be conducive in the devel-
opment of MetS through the inflammatory environment
has been suggested [15]. We did not find any significant
cause-effect changes in plasma glucose levels or oxidative
stress parameters of exogenous origin such as NEFA and
T-BARs in response to the dietary manipulation supple-
menting 20 g of mayonnaise consumption daily of either
SB- or PO-based formulations. Our findings are not in
agreement with the observations of Akter et al. [13], who
reported mayonnaise consumption, was positively associ-
ated with high blood glucose in an adult free living Japanese
population with MetS. This difference may in part be
explained by the normoglycemic status of our subjects
when recruited into the trial.
Donovan and Shamir [49] view the human diet as a
complex food matrix rather than specific nutrients, and
highlight a need to resolve how to term a food’s quality
or necessity judged as part of an individual’s whole diet.
Citing yogurt as an example, they defined its potential as
a functional food to manage lactose intolerance or bone
health, despite concerns about its high SFA content, which
is implicated in the promotion of heart disease. The
potential for mayonnaise to be a vehicle for nutraceutical
delivery has been explored with diacylglycerol in an anti-
obesity function or with plant sterol esters for decreasing
LDL-C [50, 51]. Saito et al. [51] who examined the dose-
dependent effect of a mayonnaise-type product combining
diacylglycerol with plant sterol esters in subjects with mild
hypercholesterolemia found daily ingestion of 15 g of diac-
ylglycerol plus mayonnaise containing at least 0.4 g/d of
plant sterol esters for 4 weeks significantly decreased
serum cholesterol levels. This load of mayonnaise was
similar to the planned intervention in our study.
Results of our study suggest that the active component
of SB-mayo is linoleic acid which was observed to lower
plasma LDL-C levels. Currently, mayonnaise is a condi-
ment that is commercially available as a general food prod-
uct and excessive consumption could lead to increased
lipid intake which would be counterproductive in terms of
excess calories. As scientific proof is necessary to estab-
lish the utilization of mayonnaise as a nutraceutical,
further research is necessary to determine the appropri-
ate serving size of a mayonnaise product that could
lower serum LDL-C levels.
The public health approach for heart health stresses a
~50 % reduction in SFAs to effect a reduction in LDL-C as
a means to decrease risk of CVD [1]. Quantitatively, lower-
ing SFAs by 50 % requires substitution with food sources of
ω-6 and ω–3 PUFAs and MUFAs [1, 4, 33]. Weighing the
emerging nutrition science on fatty acids and CVD, Kris-
Etherton and Fleming [33] acknowledge the best evidence
for cardioprotective benefits from substitution of SFAs re-
mains with ω–6 PUFAs, as evidence for MUFAs is mixed
whilst only relatively low amounts of ω-3 PUFAs can be
incorporated in the diet, even with very high dose. Through
this study we have provided evidence that an LA-rich may-
onnaise is a convenient vehicle for nutraceutical delivery of
the ω-6 PUFA, linoleic acid, therefore expecting a func-
tional use in reduction of LDL-C as a means to decrease
risk of CVD. The extrapolation of this study findings may
be limited to the general free living population because of
the small number of subjects (n = 34) who were relatively
young and required to consume research diets provided in
an institutional setting.
Conclusions
We demonstrated a functional role for an SB-mayo
which was rich in linoleic acid. Uptake of linoleic acid
was enhanced, accompanied by a demonstration of the
biological activities of increased ω-6 PUFA linoleate.
This was also achieved without detrimental shifts in the
overall plasma oxidative status of the subjects. These
outcomes suggest that the inclusion of about 20 g lino-
leic acid -rich mayonnaise could be managed as part of
a daily healthy diet given the current modern lifestyles
that often dictate consumption of prepared foods on
the go.
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